Progress on vaccine and antibodies against Candida albicans infections

Abstract

Abstract: Candida albicans is a commensal opportunistic fungal pathogen in human that causes superficial as well as life-threatening systemic infections in immunocompromised patients.Since the lack of diagnosis methods of candidiasis in early stage, in addition to the narrow range and significant toxicity of available antifungal agents, and the research and development of new drugs are rather difficult, the systemic candidiasis becomes the main causes resulting in death in immunocompromised patients. Therefore,antifungal treatment is still faced with severe challenges.Recently, most research has been devoted to clarify the host immune response mechanisms against C.albicans infections and try to develop the immunotherapy for C.albicans infections; so the vaccine and antibody are expected to be the effective way for prevention and treatment of fungal infections. In this article, progress in research in vaccine and antibody against C.albicans is reviewed, so as to provide a reference for the study of novel vaccine and antibody against C.albicans infections.

Key words: Candida albicans, vaccine, antibody, candidiasis infection

CLC Number:

R379.4

ZHANG Yan-xia, YAN Lan, JIANG Yuan-ying. Progress on vaccine and antibodies against Candida albicans infections[J]. Chinese Journal of Mycology, 2014, 9(1): 47-51,64.

References

[1] 陈端, 单斌, 骈淮燕, 等. 医院真菌感染 1225 例分析[J]. 中华检验医学杂志, 2005, 28(4): 387-388.
[2] Benjamin DK, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months[J]. Pediatrics, 2006, 117(1): 84-92.
[3] Bromuro C, Torosantucci A, Chiani P, et al. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine[J]. Infect Immun, 2002, 70(10): 5462-5470.
[4] Pietrella D, Rachini A, Torosantucci A, et al. A β-glucan-conjugate vaccine and anti-β-glucan antibodies are effective against murine vaginal candidiasis as assessed by a nove in vivo imaging technique[J]. Vaccine, 2010, 28(7): 1717-1725.
[5] Torosantucci A, Bromuro C, Chiani P, et al. A novel glyco-conjugate vaccine against fungal pathogens[J]. J Exp Med, 2005, 202(5): 597-606.
[6] Ho MM, Bolgiano B, Corbel MJ. Assessment of the stability and immunogenicity of meningococcal oligosaccharide C-CRM197 conjugate vaccines[J]. Vaccine, 2000, 19(7): 716-725.
[7] Read SM, Currie G, Bacic A. Analysis of the structural heterogeneity of laminarin by electrospray-ionisation-mass spectrometry[J]. Carbohydr Res, 1996, 281(2): 187-201.
[8] Bromuro C, Romano M, Chiani P, et al. Beta-glucan-CRM197 conjugates as candidates antifungal vaccines[J]. Vaccine, 2010, 28(14): 2615-2623.
[9] Rapaka RR, Goetzman ES, Zheng M, et al. Enhanced defense against Pneumocystis carinⅡ mediated by a novel dectin-1 receptor Fc fusion protein[J]. J Immunol, 2007, 178(6): 3702-3712.
[10] Rachini A, Pietrella D, Lupo P, et al. An anti-β-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo[J]. Infect Immun, 2007, 75(11): 5085-5094.
[11] Han Y, Cutler JE. Antibody response that protects against disseminated candidiasis[J]. Infect Immun, 1995, 63(7): 2714-2719.
[12] Polonelli L, Magliani W, Conti S, et al. Therapeutic activity of an engineered synthetic killer antⅡdiotypic antibody fragment against experimental mucosal and systemic candidiasis[J]. Infect Immun, 2003, 71(11): 6205-6212.
[13] Han Y, Ulrich MA, Cutler JE. Candida albicans Mannan Extract-Protein Conjugates Induce a Protective Immune Response against Experimental Candidiasis[J]. J Infect Dis, 1999, 179(6): 1477-1484.
[14] Sevilla MJ, Robledo B, Rementeria A, et al. A fungicidal monoclonal antibody protects against murine invasive candidiasis[J]. Infect Immun, 2006, 74(5): 3042-3045.
[15] Omaetxebarria M, Moragues M, Elguezabal N, et al. Antifungal and antitumor activities of a monoclonal antibody directed against a stress mannoprotein of Candida albicans[J]. Curr Mol Med, 2005, 5(4): 393-401.
[16] Brena S, Cabezas-Olcoz J, Moragues MD, et al. Fungicidal monoclonal antibody C7 interferes with iron acquisition in Candida albicans[J]. Antimicrob Agents Chemother, 2011, 55(7): 3156-3163.
[17] Xin H, Cutler JE. Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis[J]. Clin Vaccine Immunol, 2011, 18(10): 1656-1667.
[18] Segal E, Sandovsky-Losica H. Experimental vaccination with Candida albicans ribosomes in cyclophosphamide-treated animals[J]. Sabouraudia, 1981, 19(4): 267-273.
[19] Levy R, Segal E, Eylan E. Detection of antibodies against Candida albicans ribosomes by the enzyme linked immunosorbent assay[J]. Mycopathologia, 1984, 87(3): 167-170.
[20] Eckstein M, Barenholz Y, Bar L, et al. Liposomes containing Candida albicans ribosomes as a prophylactic vaccine against disseminated candidiasis in mice[J]. Vaccine, 1997, 15(2): 220-224.
[21] Levy D, Bohbot J, Catalan F, et al. Phase Ⅱ study of D. 651, an oral vaccine designed to prevent recurrences of vulvovaginal candidiasis[J]. Vaccine, 1989, 7(4): 337-340.
[22] Zhang L, Ma J, Li Y, et al. 15-Hydroxyeicosatetraenoic acid (15-HETE) protects pulmonary artery smooth muscle cells against apoptosis via HSP90[J]. Life Sci, 2010, 87(7): 223-231.
[23] Fukuizumi T, Nagamatsu H, Kojo T, et al. Induction of salivary antibodies to inhibit Candida albicans adherence to human epithelial cells by tonsillar immunization in rabbits[J]. FEMS Immunol Med Microbiol, 2006, 47(3): 398-404.
[24] Matthews R, Burnie J. Human recombinant antibody to HSP90: a natural partner in combination therapy. Curr Mol Med. 2005, 5: 403-411.
[25] Wang G, Sun M, Fang J, et al. Protective immune responses against systemic candidiasis mediated by phage-displayed specific epitope of Candida albicans heat shock protein 90 in C57BL/6J mice[J]. Vaccine, 2006, 24(35): 6065-6073.
[26] Hodgetts S, Nooney L, Al-Akeel R, et al. Efungumab and caspofungin: pre-clinical data supporting synergy[J]. J Antimicrob Chemother, 2008, 61(5): 1132-1139.
[27] Fu Y, Ibrahim AS, Sheppard DC, et al. Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway[J]. Mol Microbiol, 2002, 44(1): 61-72.
[28] Spellberg BJ, Ibrahim AS, Avanesian V, et al. Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis[J]. J Infect Dis, 2006, 194(2): 256-260.
[29] Ibrahim AS, Spellberg BJ, Avanesian V, et al. The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis[J]. Infect Immun, 2006, 74(5): 3039-3041.
[30] Spellberg B, Ibrahim AS, Lin L, et al. Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity[J]. J Infect Dis, 2008, 197(7): 967-971.
[31] Fernández-Arenas E, Molero G, Nombela C, et al. Low virulent strains of Candida albicans: unravelling the antigens for a future vaccine[J]. Proteomics, 2004, 4(10): 3007-3020.
[32] Martínez-López R, Nombela C, Diez-Orejas R, et al. Immunoproteomic analysis of the protective response obtained from vaccination with Candida albicans ecm33 cell wall mutant in mice[J]. Proteomics, 2008, 8(13): 2651-2664.
[33] Saville SP, Lazzell AL, Chaturvedi AK, et al. Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis [J]. Clin Vaccine Immunol, 2009, 16(3): 430-432.
[34] Tavares D, Ferreira P, Arala-Chaves M. Increased resistance in BALB/c mice to reinfection with Candida albicans is due to immunoneutralization of a virulence-associated immunomodulatory protein [J]. Microbiology, 2003, 149(2): 333-339.
[35] De Bernardis F, Boccanera M, Adriani D, et al. Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis [J]. Infect Immun, 2002, 70(5): 2725-2729.
[36] Vilanova M, Teixeira L, Caramalho Í, et al. Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2 [J]. Immunology, 2004, 111(3): 334-342.
[37] Sandini S, La Valle R, Deaglio S, et al. A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine [J]. FEMS Immunol Med Microbiol, 2011, 62(2): 215-224.
[38] Ibrahim E-SM, Rahman A, Isoda R, et al. In vitro and in vivo effectiveness of egg yolk antibody against Candida albicans (anti-CA IgY) [J]. Vaccine, 2008, 26(17): 2073-2080.
[39] Wang X, Fan B, Liu L, et al. In vitro inhibition of oral Candida albicans by chicken egg yolk antibody (IgY) [J]. Mycopathologia, 2008, 165(6): 381-387.
[40] Fujibayashi T, Nakamura M, Tominaga A, et al. Effects of IgY against Candida albicans and Candida spp. adherence and biofilm formation [J]. Jpn J Infect Dis, 2009, 62(5): 337-342.